Read the ten biggest stories that shaped marijuana policy in 2018.
Tag: epidiolex
Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The rescheduling change is only specific to Epidiolex, and does not amend the schedule I status of either whole-plant cannabis of CBD.
Regulators at the US Food and Drug Administration today granted market approval for Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.